Botulinum toxin for facial wrinkles: history and future

References

• Kede MPV, Sabatovich ODM. Relevance of the cosmetic use of botulinum toxin in facial rejuvenation. In: Cosmetic Use of Botulinum Toxin (1st Edition). Hexsel D, Almeida AT (Eds). AGE, Porto Alegre, Brazil 27 (2002).
   Google Scholar
• Klein AW. Treatment of wrinkles with Botox®. Curr. Probl. Dermatol.30, 188–217 (2002).
   Google Scholar
• Carruthers J, Carruthers A. The adjunctive usage of botulinum toxin. Dermatol. Surg.24, 1244–1247 (1998).
   PubMed Web of Science ®Google Scholar
• Carruthers J, Carruthers A. Botulinum toxin A in the mid and lower face and neck. Dermatol. Clin.22(2), 151–158 (2004).
   PubMed Web of Science ®Google Scholar
• Carruthers JD, Carruthers A. Treatment of glabellar frown lines with C. botulinum-A exotoxin. J. Dermatol. Surg. Oncol.18(1), 17–21 (1992).
   PubMed Web of Science ®Google Scholar
• Carruthers A, Carruthers J. Aesthetic indications for botulinic toxin injections. Plast. Reconstr. Surg.95, 427–428 (1995).
   Google Scholar
• Carruthers A, Carruthers J. Botulinum toxin type A. J. Am. Acad. Dermatol.53(2), 284–290 (2005).
   Google Scholar
• Carruthers A, Carruthers J. Botulinum toxin type A: history and current cosmetic use in the upper face. Semin. Cutan. Med. Surg.20(2), 71–84 (2001).
   PubMed Web of Science ®Google Scholar
• Carruthers J, Carruthers A. Botox use in the mid and lower face and neck. Semin. Cutan. Med. Surg.20(2), 85–92 (2001).
   Google Scholar
• Brandt FS, Bocker A. Botulinum toxin for the treatment of neck lines and neck bands. Dermatol. Clin.22(2), 159–166 (2004).
   PubMed Web of Science ®Google Scholar
• Carruthers J, Carruthers A. Aesthetic botulinum A toxin in the mid and lower face and neck. Dermatol. Surg.29(5), 468–476 (2003).
   PubMed Web of Science ®Google Scholar
• Bushara KO, Park DM, Jones JC, Schutta HS. Botulinum toxin – a possible new treatment for axillary hyperhidrosis. Clin. Exp. Dermatol.21(4), 276–278 (1996).
   PubMed Web of Science ®Google Scholar
• Glogau RG. Botulinum A neurotoxin for axillary hyperhidrosis: no sweat Botox. Dermatol. Surg.24, 817–819 (1998).
   PubMedGoogle Scholar
• Benecke R, Jost WH, Kanovsky P et al. A new botulinum type A free of complexing proteins for treatment of cervical dystonia. Neurology64(11), 1949–1951 (2005).
   PubMed Web of Science ®Google Scholar
• Jost WH, Kohl A, Brinkman S et al. Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX) in healthy volunteers. J. Neural. Transm.112(7), 905–913 (2005).
   PubMed Web of Science ®Google Scholar
• Schwetz BA. First drug for cervical dystonia. JAMA285(6), 724 (2001).
   PubMed Web of Science ®Google Scholar
• Baumann L, Slenzinger A, Vujevich J et al. A double-blinded, randomized, placebo-controlled pilot study of the safety and efficacy of Myobloc (botulinum toxin type B)-purified neurotoxin complex for the treatment of crow’s feet: a double blinded placebo-controlled trial. Dermatol. Surg.29(5), 508–515 (2003).
   Google Scholar
• Lew MF, Brashear A, Factor S. The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials. Neurology55(Suppl. 5), S29–S35 (2000).
   Web of Science ®Google Scholar
• Brin MF, Lew MF, Adler CH et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology53(7), 1431–1438 (1999).
   PubMed Web of Science ®Google Scholar
• Alster TS. Botulinum toxin type B for dynamic glabellar rhytides refractory to botulinum toxin type A. Dermatol. Surg.29(5), 516–518 (2003).
   PubMed Web of Science ®Google Scholar
• Baumann L, Slezinger A, Halem M et al. Pilot study of the safety and efficacy of Myobloc™ (botulinum toxin type B) for treatment of axillary hyperhidrosis. Int. J. Dermatol.44(5), 418–424 (2005).
   PubMed Web of Science ®Google Scholar
• Product literature (package insert) on Botox®. Allergan, Inc., CA, USA (2002).
   Google Scholar
• Product literature (package insert) on Dysport®. Ipsen Products, Berkshire, UK (2002).
   Google Scholar
• Dressler D, Benecke R. Xeomin®: perspectives of a novel therapeutic botulinum toxin preparation. Akt. Neurol.33, 138–141 (2006).
   Web of Science ®Google Scholar
• Feller G, Bayeri C, Jung EG et al. Treatment of dynamic facial wrinkles with botulinum toxin A (Dysport). Akt. Dermatol.25, 1–5 (1999).
   Google Scholar
• Lowe NJ. Botulinum toxin type A for facial rejuvenation: United States and United Kingdom perspectives. Dermatol. Surg.24, 1216–1218 (1998).
   Google Scholar
• Sampaio C, Ferreira JJ, Simoes F et al. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerance of two formulations of botulinum toxin type A – Dysport® and Botox® – assuming a ratio 4:1. Mov. Disord.12(6), 1013–1018 (1997).
   PubMed Web of Science ®Google Scholar
• Odergren T, Hjaltason H, Kaakkola S et al. A double blind, randomized, parallel group study to investigate the dose equivalences of Dysport® and Botox® in the treatment of cervical dystonia. J. Neurol. Neurosurg. Psychiatr.64(1), 6–12 (1998).
   PubMed Web of Science ®Google Scholar
• Ranoux D, Gury C, Fondarai J et al. Respective potencies of Botox and Dysport: a double blind, randomized, crossover study in cervical dystonia. J. Neurol. Neurosurg. Psychiatr.72, 459–462 (2002).
   PubMed Web of Science ®Google Scholar
• Wohlfarth K, Wegner F, Schwandt I et al. Pharmacokinetic properties of different preparations of botulinum neurotoxin type A. Poster presented at: 5th International Conference on the Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins. CO, USA, 23–25 June 2005.
   Google Scholar
• Poewe W. Respective potencies of Botox and Dysport: a double blind, randomized, crossover study in cervical dystonia: clinically appropriate conversion factor may be less than three. J. Neurol. Neurosurg. Psychiatry72(4), 430 (2002).
   PubMed Web of Science ®Google Scholar
• Tsui JKC. Botulinum toxin as a therapeutic agent. Pharmacol. Ther.72(1), 13–24 (1996).
   PubMed Web of Science ®Google Scholar
• Simpson LL. Molecular pharmacology of botulinum toxin and tetanus toxin. Annu. Pharmacol. Toxicol.26, 427–453 (1986).
   PubMed Web of Science ®Google Scholar
• Keller JE, Neale EA. The role of the synaptic protein snap-25 in the potency of botulinum neurotoxin type A. J. Biol. Chem.276(16), 13476–13482 (2001).
   PubMed Web of Science ®Google Scholar
• Dal’Forno TO, Zechmeister M. Material used in botulinum toxin application. In: Cosmetic Use of Botulinum Toxin (1st Edition). Hexsel D, Almeida AT (Eds). AGE, Porto Alegre, Brazil 46–47 (2002).
   Google Scholar
• Louarn CL. Botulinum toxin A and facial lines: the variable concentration. Aesth. Plast. Surg.25, 73–84 (2001).
   Google Scholar
• Carruthers A, Carruthers J. Cosmetic uses of botulinum A exotoxin. Adv. Dermatol.12, 325–347 (1997).
   Google Scholar
• Kwait DM, Bersani TA, Bersani A. Increased patient comfort utilizing botulinum toxin type A reconstituted with preserved versus non preserved saline. Ophthal. Plast. Reconstr. Surg.20(3), 186–189 (2004).
   Google Scholar
• Alam M, Dover JS, Arndt KA. Pain associated with injection of botulinum A exotoxin reconstituted using isotonic sodium chloride with and without preservative. A double-blind, randomized controlled trial. Arch. Dermatol.138(4), 510–514 (2002).
   PubMedGoogle Scholar
• Klein AW. Contraindications and complications with the use of botulinum toxin. Clin. Dermatol.22(1), 66–75 (2004).
   PubMedGoogle Scholar
• Product literature (package insert) on Prosigne®. Lanzhou Institute of Biological Products, China (2005).
   Google Scholar
• Hexsel D, Almeida AT, Rutowitch MS et al. Multicenter, double-blind study of the efficacy of injections with botulinum toxin A reconstituted in 6 consecutive weeks prior to application. Dermatol. Surg.29, 523–529 (2003).
   PubMed Web of Science ®Google Scholar
• Frampton JE, Easthope SE. Botulinum toxin A (Botox cosmetic): a review of its use in the treatment of glabellar frow lines. Am. J. Clin. Dermatol.4(10), 709–725 (2003).
   Google Scholar
• Carruthers A. Botulinum toxin type A: history and current cosmetic use in the upper face. Dis. Mon.48(5), 299–322 (2002).
   PubMed Web of Science ®Google Scholar
• Carruthers JA, Lowe NJ, Menter MA et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J. Am. Acad. Dermatol.46(6), 840–849 (2002).
   PubMed Web of Science ®Google Scholar
• Klein AW. Complications and adverse reactions with the use of botulinum toxin. Semin. Cutan. Med. Surg.2, 109–120 (2001).
   Google Scholar
• Costa OC, Succi ICB. Contra-indicações e precauções. In: Uso Cosmético da Toxina Botulínica. Hexsel D, Almeida AT (Eds). AGE, Porto Alegre, Brazil 134–136 (2002).
   Google Scholar
• Sommer B, Lowe N. Cosmetic indications. In: Handbook of Botulinum Toxin Treatment (2th Edition). Moore P, Naumann M (Eds). Blackwell Science, Oxford, UK 422–437 (2003).
   Google Scholar
• Wollina U, Konrad H. Managing adverse events associated with botulinum toxin type A. Am. J. Clin. Dermatol.6(3), 141–160 (2005).
   PubMed Web of Science ®Google Scholar
• Sattler G. Patient management and treatment technique. Clin. Dematol.21, 485–487 (2003).
   Google Scholar
• Hexsel D, Mazzuco R, Zechmeister M et al. Complications and adverse affects: diagnosis and treatment. In: Cosmetic Use of Botulinum Toxin. Hexsel D, Almeida AT (Eds). AGE, Porto Alegre, Brazil 233–239 (2002).
   Google Scholar
• Matarasso SL, Matarasso A. Treatment guidelines for botulinum toxin type A for the periocular region and a report on partial upper lip ptosis following injections to the lateral canthal rhytids. Plast. Reconstr. Surg.108, 208–217 (2001).
   Google Scholar
• Frankel AS. Botox for rejuvenation of the periorbital region. Facial Plast. Surg.15(3), 255–262 (1999).
   PubMedGoogle Scholar
• Maia RB. Post-operative care. In: Cosmetic Use of Botulinum Toxin. Hexsel D, Almeida AT (Eds). AGE, Porto Alegre, Brazil 141–142 (2002).
   Google Scholar
• Hsu TS, Dover JS, Kaminer MS et al. Why make patients exercise facial muscles for 4 hours after botulinum toxin treatment? Arch. Dermatol.139(7), 948 (2003).
   PubMedGoogle Scholar
• Smith K. Fifth World Congress of the International Academy of Cosmetic Dermatology (IACD). Melbourne, Australia, 9–13 December 2006.
   Google Scholar
• Hexsel D, Dal’Forno T. Type A botulinum toxin in the upper aspect of the face. Clin. Dermatol.21, 488–497 (2003).
   Google Scholar
• Carruthers A, Carruthers J. Botulinum toxin type A for the treatment of glabelar rhytides. Dermatol. Clin.22(2), 137–144 (2004).
   Google Scholar
• Flynn TC. Update on botulinum toxin. Semin. Cutan. Med. Surg.25(3), 115–121 (2006).
   Google Scholar
• Carruthers A, Carruthers J. Prospective, double-blind, randomized, parallel group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatol. Surg.31(10), 1297–1303 (2005).
   PubMed Web of Science ®Google Scholar
• Carruthers A, Carruthers J, Said S. Dose-ranging study of botulinum toxin type A in the treatment of glabelar rhytids in females. Dermatol. Surg.31(4), 414–422 (2005).
   PubMed Web of Science ®Google Scholar
• Ascher B, Zakine B, Kestemont P, Baspeyras M, Bougara A, Santini J. A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabelar lines. J. Am. Acad. Dermatol.51(2), 223–233 (2004).
   PubMed Web of Science ®Google Scholar
• Carruthers A, Carruthers J. Clinical indications and injection technique for the cosmetic use of botulinum A exotoxin. Dermatol. Surg.24(11), 1189–1194 (1998).
   PubMedGoogle Scholar
• Carruthers JA, Lowe NJ, Menter MA et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J. Am. Acad. Dermatol.46(6), 840–849 (2002).
   PubMed Web of Science ®Google Scholar
• Rzany B, Ascher B, Fratila A et al. Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport®) for the treatment of wrinkles in the glabella and the central forehead region. Arch. Dermatol.142(3), 320–326 (2006).
   PubMedGoogle Scholar
• Carruthers J, Fagien S, Matarasso SL; Botox Consensus Group. Consensus recommendations on the use of botulinum toxin type A in facial aesthetics. Plast. Reconstr. Surg.114(6 Suppl.), 1S–22S (2004).
   PubMed Web of Science ®Google Scholar
• Beer K, Yohn M, Closter J. A double-blinded, placebo-controlled study of Botox® for the treatment of subjects with chin rhytids. J. Drugs Dermatol.4(4), 417–422 (2005).
   PubMedGoogle Scholar
• Hexsel D, Mazzuco R, Oliveira T, Hexsel CL. Aplicações não-clássicas. In: Dermatologia Estética. Kede P, Sabatovitch O (Eds). Atheneu, Rio de Janeiro, Brazil 573–581 (2003).
   Google Scholar
• Mazzuco R. Rugas peri-orais. In: Uso Cosmético da Toxina Botulínica. Hexsel D, Almeida AT (Eds). AGE, Porto Alegre, Brazil 158–163 (2002).
   Google Scholar
• Cote TR, Mohan AK, Polder JA, Walton MK, Braun MM. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J. Am. Acad. Dermatol.53(3), 407–415 (2005).
   PubMed Web of Science ®Google Scholar
• Benedetto AV. The cosmetic uses of botulinum toxin type A. Int. J. Dermatol.38(9), 641–655 (1999).
   PubMed Web of Science ®Google Scholar
• Sadick NS. Overview of complications of nonsurgical facial rejuvenation procedures. Clin. Plast. Surg.1, 163–176 (2001).
   Google Scholar
• Borodic G, Johnson E, Goodnough M, Schantz E. Botulinum toxin therapy, immunologic resistance, and problems with available materials. Neurology46, 26–29 (1996).
   PubMed Web of Science ®Google Scholar
• Hexsel D, Costa RO, Mazzuco R, Hexsel CL. Efeitos adversos e complicações da toxina botulínica. In: Tratado de Medicina Estética (Volume II). Maio M, Isaac C (Eds). Roca, São Paulo, Brazil 1373–1384 (2004).
   Google Scholar
• Markey AC. Botulinum A exotoxin in cosmetic dermatology. Clin. Dermatol.25(3), 173–175 (2000).
   Google Scholar
• Wieder JM, Moy RL. Understanding botulinum toxin. Dermatol. Surg.24, 1172–1174 (1998).
   Google Scholar
• Garcia A, Fulton JE Jr. Cosmetic denervation of the muscles of facial expression with botulinum toxin. Dermatol. Surg.22, 39–43 (1996).
   PubMedGoogle Scholar
• Coroneo MT, Rosenberg ML, Cheung LM. Ocular effects of cosmetic products and procedures. Ocul. Surf.4(2), 94–102 (2006).
   Google Scholar
• Northington ME, Huang CC. Dry eyes and superficial punctuate keratitis: a complication of treatment of glabelar dynamic rhytides with botulinum exotoxin A. Dermatol. Surg.30(12 Pt 2), 1515–1517 (2004).
   Google Scholar
• Matarasso SL. Complications of botulinum A exotoxin for hyperfunctional lines. Dermatol. Surg.24, 1249–1254 (1998).
   PubMed Web of Science ®Google Scholar
• Manaloto RMP, Alster TS. Periorbital rejuvenation: a review of dermatologic treatments. Dermatol. Surg.25, 1–8 (1999).
   PubMed Web of Science ®Google Scholar
• Carruthers A, Kiene K, Carruthers J. Botulinum A exotoxin use in clinical dermatology. J. Am. Acad. Dermatol.34(5), 788–797 (1996).
   PubMedGoogle Scholar
• Misra VP. The changed image of botulinum toxin. Br. Med. J.325(7374), 1188 (2002).
   PubMed Web of Science ®Google Scholar
• Gill DM. Bacterial toxins: a table of lethal amounts. Microbiol. Rev.46, 86–94 (1982).
   PubMedGoogle Scholar
• Ravichandran E, Gong Y, Al Saleen FH et al. An initial assessment of the systemic pharmacokinetics of botulinum toxin. J. Pharmacol. Exp. Ther.318(3), 1343–1351 (2006).
   PubMed Web of Science ®Google Scholar
• Papapetropoulos S, Singer C. Treatment of primary writing tremor with botulinum toxin type A injections: report of a case series. Clin. Neuropharmacol.29(6), 364–367 (2006).
   PubMedGoogle Scholar
• Lucioni A, Rapp DE, Gong EM et al. Intravesical botulinum type A toxin injection in patients with overactive bladder: trigone versus trigone-sparing injection. Can. J. Urol.13(5), 3291–3295 (2006).
   PubMedGoogle Scholar
• Chuang YC, Chiang PH, Yoshimura N et al. Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia. Br. J. Urol.98(5), 1033–1037 (2006).
   Google Scholar
• Albani G, Petroni ML, Mauro A et al. Safety and efficacy of therapy with botulinum toxin in obesity: a pilot study. J. Gastroenterol.40, 833–835 (2005).
   Google Scholar
• Carruthers JA, Carruthers A. A prospective, randomized, parallel group study analyzing the effect of BTX-A (Botox) and nonanimal sourced hyaluronic acid (NASHA, Restylane) in combination compared with NASHA (Restylane) alone in severe glabellar rhytides in adult female subjects: treatment of severe glabellar rhytides with a hyaluronic acid derivative compared with derivative and BTX-A. Dermatol. Surg.29, 802–809 (2003).
   PubMed Web of Science ®Google Scholar
• Carruthers JA, Carruthers A. Facial sculpting and tissue augmentation. Dermatol. Surg.31, 1604–1612 (2005).
   PubMed Web of Science ®Google Scholar
• Matarasso SL. The use of injectable collagen for aesthetic rejuvenation. Semin. Cutan. Med. Surg.25, 151–157 (2006).
   PubMed Web of Science ®Google Scholar
• Carruthers JA, Carruthers A. The effect of broadband light treatments alone and in combination with bilateral crow’s feet botulinum toxin type A chemodenervation. Dermatol. Surg.30, 355–356 (2004).
   PubMed Web of Science ®Google Scholar
• Yamauchi PS, Lask G, Lowe NJ. Botulinum toxin type A gives adjunctive benefit to periorbital laser resurfacing. J. Cosmet. Laser Ther.6, 145–148 (2004).
   PubMedGoogle Scholar
• Semchyshyn NL, Kilmer SL. Does laser inactive botulinum toxin? Dermatol. Surg.31, 399–404 (2005).
   PubMedGoogle Scholar
• Flynn TC, Clark RE. Botulinum toxin type B (Myobloc) versus botulinum toxin type A (Botox) frontalis study rate of onset and radium of diffusion. Dermatol. Surg.29, 519–522 (2003).
   PubMed Web of Science ®Google Scholar
• Beer KR. Comparative evaluation of the safety and efficacy of botulinum toxin type A and topical creams for treating moderate to severe glabellar rhytids. Dermatol. Surg.32, 184–192 (2006).
   Google Scholar
• Hund T, Ascher B, Rzany B. Reproducibility of two four-point clinical severity scores for lateral canthal lines. Dermatol. Surg.32, 1256–1260 (2006).
   PubMedGoogle Scholar
• Day DJ, Littler CM, Swift RW, Gottlieb S. The wrinkle severity scale: a validation study. Am. J. Clin. Dermatol.5, 49–52 (2004).
   PubMed Web of Science ®Google Scholar
• Lamperle G, Holmes RE, Cohen SR, Lamperle SM. A classification of facial wrinkles. Plast. Reconstr. Surg.108, 1735–1750 (2001).
   Google Scholar
• Kim EJ, Reeck JB, Maas CS. A validated rating scale for hyperkinetic facial lines. Arch. Facial Plast. Surg.6, 253–256 (2004).
   Google Scholar
• Simpson LL. Identification of the major steps in botulinum toxin action. Annu. Rev. Pharmacol. Toxicol.44, 167–193 (2004).
   PubMed Web of Science ®Google Scholar